Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 19/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.56 |
| ▸ | MTOR | P42345 | 1/20 | 0.56 |
| ▸ | PIK3CB | P42338 | 13/20 | 0.56 |
| ▸ | PIK3CG | P48736 | 13/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1194119 | 0.97 | PIK3CD (0.57) | PIK3CDPIK3CAMTORPIK3CBPIK3CG | |
| SCHEMBL1193852 | 0.89 | PIK3CD (0.71) | PIK3CDPIK3CAMTORPIK3CBPIK3CG | |
| SCHEMBL1194396 | 0.88 | PIK3CD (0.52) | PIK3CDPIK3CAMTORPIK3CBPIK3CG | |
| SCHEMBL2690205 | 0.88 | PIK3CD (0.56) | PIK3CDPIK3CAMTORPIK3CBPIK3CG | |
| SCHEMBL1194360 | 0.87 | PIK3CD (0.57) | PIK3CDPIK3CAMTORPIK3CBPIK3CG | |
| SCHEMBL1193909 | 0.87 | PIK3CD (0.60) | PIK3CDPIK3CAMTORPIK3CBPIK3CG | |
| SCHEMBL1194189 | 0.86 | PIK3CD (0.55) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL4401457 | 0.86 | PIK3CD (0.55) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1194326 | 0.86 | PIK3CD (0.78) | PIK3CDPIK3CAMTORPIK3CBPIK3CG | |
| SCHEMBL1195224 | 0.84 | PIK3CD (0.58) | PIK3CDPIK3CAMTORPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168633-B2 | Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase | GENENTECH, INC. (US) | 2012-05-01 | — | — | US | claimed |
| EP-2158207-B1 | THIAZOLIOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | HOFFMANN LA ROCHE (CH) | 2011-05-25 | — | — | EP | claimed |
| US-20110098270-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | HANCOX TIMOTHY COLIN | 2011-04-28 | — | — | US | claimed |
| US-7893060-B2 | Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase | F. HOFFMANN-LA ROCHE AG (GB) | 2011-02-22 | — | — | US | claimed |
| US-20100190769-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-29 | — | — | US | claimed |
| US-8168633-B2 | Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase | GENENTECH, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168633-B2 | Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase | GENENTECH, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168633-B2 | Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase | GENENTECH, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| EP-2158207-B1 | THIAZOLIOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | HOFFMANN LA ROCHE (CH) | 2011-05-25 | — | — | EP | disclosed |
| EP-2158207-B1 | THIAZOLIOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | HOFFMANN LA ROCHE (CH) | 2011-05-25 | — | — | EP | disclosed |
| US-20110098270-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | HANCOX TIMOTHY COLIN | 2011-04-28 | — | — | US | disclosed |
| US-20110098270-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | HANCOX TIMOTHY COLIN | 2011-04-28 | — | — | US | disclosed |
| US-20110098270-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | HANCOX TIMOTHY COLIN | 2011-04-28 | — | — | US | disclosed |
| US-7893060-B2 | Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase | F. HOFFMANN-LA ROCHE AG (GB) | 2011-02-22 | — | — | US | disclosed |
| US-7893060-B2 | Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase | F. HOFFMANN-LA ROCHE AG (GB) | 2011-02-22 | — | — | US | disclosed |
| US-7893060-B2 | Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase | F. HOFFMANN-LA ROCHE AG (GB) | 2011-02-22 | — | — | US | disclosed |
| US-20100190769-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-29 | — | — | US | disclosed |
| US-20100190769-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-29 | — | — | US | disclosed |
| US-20100190769-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-29 | — | — | US | disclosed |
| WO-2008152390-A1 | THIAZOLIOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190769-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | PDPK1, PIK3CA, PI4KA | PIK3CD 4/4885PIK3CA 2/4885MTOR 26/4885 |
| US-20110098270-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | PIK3CA, PIK3CD, PI4KA | PIK3CD 2/4885PIK3CA 1/4885MTOR 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.